One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Focus on heart failure and cardiomyopathies: new ESC Guidelines and key meta-analyses
Filippo Crea
doi : 10.1093/eurheartj/ehad647
European Heart Journal, Volume 44, Issue 37, 1 October 2023, Pages 3487–3491
The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients
J. Hans DeVries 1,2*, Alar Irs 3, and Hans L. Hillege
Role of the extracellular matrix in cell–cell communication: a new therapeutic target?
Thorsten Kessler 1,2 *, Hendrik B. Sager 1,2 , and Matthias Mann
Space and precision cardiovascular health: future perspectives of space travel
Chayakrit Krittanawong 1 * and Richard A. Scheuring
An unexpected fall from GRACE
Daniela Pedicino 1* and Giovanna Liuzzo
2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)
Elena Arbelo *†, (Chairperson) (Spain), Alexandros Protonotarios ‡, (Task Force Co-ordinator) (United Kingdom), Juan R. Gimeno ‡, (Task Force Co-ordinator) (Spain), Eloisa Arbustini (Italy), Roberto Barriales-Villa (Spain), Cristina Basso (Italy), Connie R. Bezzina (Netherlands), Elena Biagini (Italy), Nico A. Blom1 (Netherlands), Rudolf A. de Boer (Netherlands), Tim De Winter (Belgium), Perry M. Elliott (United Kingdom), Marcus Flather (United Kingdom), Pablo Garcia-Pavia (Spain), Kristina H. Haugaa (Sweden), Jodie Ingles (Australia), Ruxandra Oana Jurcut (Romania), Sabine Klaassen (Germany), Giuseppe Limongelli (Italy), Bart Loeys 2 (Belgium), Jens Mogensen (Denmark), Iacopo Olivotto (Italy), Antonis Pantazis (United Kingdom), Sanjay Sharma (United Kingdom), J. Peter Van Tintelen (Netherlands), James S. Ware (United Kingdom), Juan Pablo Kaski *†, (Chairperson) (United Kingdom), and ESC Scientific Document Group
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC
Theresa A. McDonagh *†, (Chairperson) (United Kingdom), Marco Metra *†, (Chairperson) (Italy), Marianna Adamo ‡, (Task Force Co-ordinator) (Italy), Roy S. Gardner ‡, (Task Force Co-ordinator) (United Kingdom), Andreas Baumbach (United Kingdom), Michael B?hm (Germany), Haran Burri (Switzerland), Javed Butler (United States of America), Jelena ?elutkien? (Lithuania), Ovidiu Chioncel (Romania), John G.F. Cleland (United Kingdom), Maria Generosa Crespo-Leiro (Spain), Dimitrios Farmakis (Greece), Martine Gilard (France), Stephane Heymans (Netherlands), Arno W. Hoes (Netherlands), Tiny Jaarsma (Sweden), Ewa A. Jankowska (Poland), Mitja Lainscak (Slovenia), Carolyn S.P. Lam (Singapore), Alexander R. Lyon (United Kingdom), John J.V. McMurray (United Kingdom), Alexandre Mebazaa (France), Richard Mindham (United Kingdom), Claudio Muneretto (Italy), Massimo Francesco Piepoli (Italy), Susanna Price (United Kingdom), Giuseppe M.C. Rosano (United Kingdom), Frank Ruschitzka (Switzerland), Anne Kathrine Skibelund (Denmark), and ESC Scientific Document Group
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun K. Pandey1 , Deepak L. Bhatt 2 , Avinash Pandey3 , Nikolaus Marx 4 , Francesco Cosentino 5,6 , Ambarish Pandey 7 , and Subodh Verma
REVIV(E)ing the ischaemic paradigm in heart failure: STICHes are needed
Luis E. Rohde 1,2,3* and John J.V. McMurray
Beta-blockers in non-obstructive hypertrophic cardiomyopathy: time to ease the heart rate restriction?
Adaya Weissler-Snir1,2*, Harry Rakowski3, and Markus Meyer
Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials
Pascal R. D. Clephas 1†, Sumant P. Radhoe 1†, Eric Boersma1 , John Gregson2 , Pardeep S. Jhund3 , William T. Abraham 4 , John J. V. McMurray 3 , Rudolf A. de Boer 1 , and Jasper J. Brugts
Remote heart failure management guided by pulmonary artery pressure home monitoring: rewriting the future?
Christiane E. Angermann 1,2* and Georg Ertl
Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial
Evelyne Meekers 1,2†, Jeroen Dauw 2,3†, Pieter Martens1,4, Sebastiaan Dhont 1,2, Frederik H. Verbrugge5,6, Petra Nijst 1, Jozine M. ter Maaten7, Kevin Damman 7, Alexandre Mebazaa8, Gerasimos Filippatos9, Frank Ruschitzka10, Wai Hong Wilson Tang4, Matthias Dupont 1, and Wilfried Mullens
Acetazolamide for acute heart failure: is ADVOR a riddle wrapped in a mystery inside an enigma?
Héctor Bueno 1,2,3,4* and Milton Packer
Mineralocorticoid receptor antagonists with sodium–glucose co-transporter-2 inhibitors in heart failure: a meta-analysis
Mainak Banerjee 1*, Indira Maisnam1, Rimesh Pal2, and Satinath Mukhopadhyay
Sodium–glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists synergism in heart failure: it takes two to tango
Johann Bauersachs * and Samira Soltani
Detailed safety analysis of DIAMOND trial: ‘primum non nocere’?
Rui Baptista 1*, Sara Gonçalves2, and Ricardo Fontes-Carvalho
Carat, clarity, colour, and cut: grading the DIAMOND trial
Javed Butler 1*, Jefferey Budden2, Bertram Pitt 3, and Stefan Anker
Histiocytes from the body to the heart: a complex case of cardiac and multi-organ involvement of Erdheim–Chester disease
Antonio Iaconelli 1*, Lucia Leccisotti2, Giuseppe Rovere3, Aureliano Ruggio1, and Filippo Crea
Skin lesions, weight loss, and ventricular tachycardia: connecting the dots to diagnose multisystemic sarcoidosis
Correction to: Lifelong endurance exercise and its relation with coronary atherosclerosis
